mevalonic acid has been researched along with Malignant Mesothelioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badhai, J; Beijersbergen, R; Hulsman, D; Janes, SM; Kolluri, KK; Landman, N; Lieftink, C; Neikes, HK; Pandey, GK; van Lohuizen, M; Vermeulen, M | 1 |
| Hida, T; Horio, Y; Murakami-Tonami, Y; Osada, H; Sekido, Y; Tanaka, K | 1 |
2 other study(ies) available for mevalonic acid and Malignant Mesothelioma
| Article | Year |
|---|---|
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.
Topics: Animals; Cholesterol; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mevalonic Acid; Mice; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2023 |
Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Neoplastic; Hippo Signaling Pathway; Humans; Hyaluronan Receptors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mevalonic Acid; Mutation; Neoplasm Invasiveness; Neoplastic Stem Cells; Neurofibromin 2; Phosphoproteins; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; Signal Transduction; Simvastatin; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; YAP-Signaling Proteins | 2017 |